Announcement • Mar 27
Daxor Corporation Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Daxor Corporation announced that new clinical data evaluating the accuracy of capillary leak detection scores compared to BVA was presented at the Society for Critical Care Medicine 2026 Critical Care Congress. The study, titled, 'Mechanistic Specificity of Capillary Leak Indices: Validation in Heart Failure as a Negative Control,' was featured during the Research Snapshot Theater. The research investigated the relationship between traditional clinical scoring methods and direct, in-vivo measurement of albumin escape using Daxor’s Blood Volume Analyzer. Capillary leak occurs when the walls of the blood vessels become permeable, allowing fluid and proteins to escape from the bloodstream into the surrounding tissue (edema). The study utilized Daxor’s BVA system to measure the Albumin Escape Rate—the actual fraction of intravascular albumin leaking across the capillary wall per hour. Researchers compared these direct measurements against four common clinical indices (including the Capillary Leak Index and SOFA score) in a heart failure cohort. Key findings include: The BVA system identified significantly elevated albumin escape rates in patients, even when traditional clinical scores remained 'uniformly low.' Clinical indices showed weak and non-significant correlations with actual albumin escape, suggesting that these common scores may miss significant vascular leakage in the arena of heart failure, considered a non-inflammatory setting. The research confirms that while common clinical scores are designed to detect inflammatory leak (like sepsis), their actual accuracy remains unproven. Daxor’s BVA is the only tool capable of directly measuring albumin leak, including patients with heart failure and sepsis, filling a critical diagnostic gap. Future proposed studies intend to show whether clinical scores are valid in inflammatory leak, or whether in that domain as well, only Daxor’s technology remains the reliable metric of direct measurement of a high albumin leak rate. This data reinforces Daxor’s position as the sole provider of objective, real-time albumin leak rate as well as volume measures. The unique combination of highly accurate and direct volume measurement and leak rate analysis expands the clinical benefit of the test deep into the critical care and heart failure markets, where differentiating the underlying status of a patient's fluid imbalance is essential for proper treatment and precision medicine. Announcement • Mar 18
Daxor Corporation Showcases Next-Generation Portable Blood Volume Analyzer At ACC.26 Daxor Corporation announced its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans, LA, March 28–30, 2026. Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA). As the only FDA-cleared diagnostic providing greater than 95% accurate, direct quantification of a patient’s total blood, plasma, and red cell volume, the BVA replaces subjective guesswork with definitive data. This precision is a critical benefit of BVA, particularly for health systems navigating the $3.5 billion annual Medicare burden of heart failure readmissions in the United States. Peer-reviewed studies demonstrate that BVA-guided care results in a 56% reduction in 30-day readmissions and an 82% reduction in 30-day mortality, delivering a transformative value proposition that aligns the interests of clinicians, hospital administrators, and payers alike. Daxor is exhibiting at Booth #1557, where it will demonstrate how its portable technology is poised to scale across inpatient and outpatient care environments. Announcement • Mar 10
Daxor Corporation Showcases New Portable Blood Volume Analyzer Daxor Corporation announced it will showcase its new, portable blood volume analyzer at the Society for Critical Care Medicine 2026 Critical Care Congress (Booth #906) at McCormick Place in Chicago, IL, from March 22–24. The new device delivers rapid, lab-quality results making Blood Volume Analysis (BVA) easier to implement across diverse clinical settings. This streamlined workflow positions Daxor to address the high costs associated with the more than five million annual adult ICU admissions in the U.S., which currently exceed $100 billion in annual healthcare spending. 
